Lymphoedema — diagnosis, complex decongestive therapy and AU care pathways

Lymphoedema is chronic swelling caused by failure of the lymphatic system to drain interstitial fluid adequately, resulting in protein-rich oedema that, over time, induces fibrosis, fat deposition, and skin changes. It affects approximately 10–15% of cancer survivors after nodal dissection or radiation, making it one of the most common long-term treatment effects in Australian oncology. It also occurs in primary forms — congenital or developmental — and secondary to obesity, recurrent cellulitis, chronic venous insufficiency, immobility, or in the context of filariasis in patients from tropical or endemic regions. The condition is lifelong, not reversible with elevation alone, and requires early specialist-guided intervention to prevent progression to the more severe fibrotic stages where management becomes substantially harder.

A. Core clinical — the AU general-practice framework

Classification

Primary lymphoedema — genetic or developmental:

• Congenital (Milroy disease) — onset before 1 year; bilateral lower limbs; FLT4 or VEGFR3 mutation
• Lymphoedema praecox (Meige) — onset puberty to 35 years; commonest primary form; lower limb; FOXC2 mutation
• Lymphoedema tarda — onset after 35 years; rare

Secondary lymphoedema — the predominant form in Australian general practice:

• Cancer treatment-related — breast cancer (axillary node dissection or radiation → upper limb, ~15–20%); endometrial, cervical, ovarian, prostate cancer (pelvic node dissection or radiation → lower limb, ~20–25%); melanoma (sentinel or completion lymphadenectomy); head and neck cancer
• Recurrent cellulitis — progressive lymphatic damage from repeated infection
• Obesity — chronic compression of lymphatics; partially reversible with weight loss
• Chronic venous insufficiency (phlebolymphoedema) — mixed venous and lymphatic failure; common in older adults
• Immobility and dependency — bedbound patients, limb paralysis
• Filariasis — Wuchereria bancrofti; tropical or migrant context; specialist tropical medicine referral

International Society of Lymphology staging

The ISL 2020 Consensus Document defines four stages, which guide treatment intensity:

Stage	Description	Clinical features
0 (latent)	No visible swelling; reduced lymphatic transport; subclinical	High-risk patient, e.g. post-mastectomy; swelling not present
1 (early)	Pitting oedema; reduces with elevation; soft	Morning reduction; Stemmer’s sign may be negative early
2 (moderate)	Non-pitting; does not reduce with elevation; fibrotic	Positive Stemmer’s sign; skin thickening
3 (severe / elephantiasis)	Gross enlargement; papillomatosis; fibrosis; hyperkeratosis; recurrent cellulitis	Skin folds with bacterial/fungal entry points

Diagnosis — clinical examination

The clinical diagnosis of lymphoedema is based on:

1. History — cancer treatment or surgery involving nodal dissection or radiation; prior cellulitis; family history (primary); timeline of onset; triggering event
2. Limb measurement — circumferential measurements at defined landmarks; compare both limbs; >2 cm difference at any point is clinically significant; volume displacement is the gold standard
3. Stemmer’s sign — attempt to pinch and lift the skin at the base of the second toe or second finger. Positive Stemmer’s sign — skin cannot be lifted — is specific for lymphoedema
4. Skin assessment — texture, pitting vs non-pitting character, dorsal foot or hand involvement (specific to lymphoedema), papillomatosis, hyperkeratosis, skin fold formation, entry-point breaks
5. Pitting test — press firmly for 5 seconds; pitting (Godet sign) indicates fluid-phase oedema; non-pitting indicates proteinaceous fibrosis of stage 2 or higher

Distinguishing lymphoedema from venous oedema is the most important clinical step:

Feature	Lymphoedema	Venous oedema
Dorsal foot involvement	✔ characteristic	✗ typically spared
Stemmer’s sign	Positive	Negative
Pitting character	Early: pitting; later: non-pitting	Pitting
Haemosiderin pigmentation	Absent	Present (brown discolouration, gaiter area)
Varicose veins	Not required	Common
Skin ulceration	Uncommon (unless late stage)	Gaiter-area leg ulcers common
Elevation	Partial reduction early; no reduction stage 2+	Reduces overnight

Workup

• Lymphoscintigraphy — gold standard for confirming lymphatic obstruction; maps collateral pathways; guides CDT planning. Arrange via nuclear medicine.
• Duplex ultrasound — essential to exclude deep vein thrombosis and assess venous insufficiency component in lower-limb swelling
• ICG fluorescence lymphography — emerging, available in specialist centres; outlines lymphatic anatomy in real time
• Bioelectrical impedance spectroscopy (BIS) — early detection of subclinical lymphoedema (stage 0); L-Dex device
• FBC, renal function, albumin, BNP — to exclude systemic causes of oedema: cardiac failure, renal disease, hepatic disease, hypoalbuminaemia

Management — complex decongestive therapy

Complex decongestive therapy (CDT) is the international standard of care, endorsed by the Australasian Lymphology Association (ALA), ISL 2020, and Cancer Australia. CDT has two phases:

Phase 1 — Intensive (2–4 weeks, typically daily sessions):

• Manual lymphatic drainage (MLD) — gentle rhythmic massage directing lymph toward functioning lymph nodes via collateral pathways; performed by a certified therapist
• Multilayer short-stretch compression bandaging — applied immediately after MLD to maintain reduction achieved
• Skin care — moisturisation, pH-neutral soap, nail care, treatment of any fungal or bacterial entry points
• Exercise with compression — movements that use the muscle-pump to assist lymphatic return

Phase 2 — Maintenance (ongoing, lifelong):

• Graduated compression garments — flat-knit, Class II (23–32 mmHg) or higher for significant lymphoedema; fitted by the therapist; replace every 6 months
• Self-MLD — simplified home technique taught by therapist
• Ongoing exercise
• Daily skin care
• Monitoring for cellulitis and prompt treatment

Refer via the ALA certified therapist directory — therapists with the post-nominals CLT (Certified Lymphoedema Therapist) or ALA Member carry adequate training.

B. Evidence — CDT and compression

The ISL 2020 Consensus and Cancer Australia evidence review support CDT as the most effective intervention for reducing limb volume and improving quality of life in established lymphoedema. Systematic reviews confirm that compression garments in the maintenance phase prevent re-accumulation of fluid after intensive CDT. Without maintenance compression, volume reduction achieved in phase 1 is lost within weeks.

Cellulitis and prophylactic antibiotics: patients with lymphoedema who have two or more episodes of cellulitis per year have a Cochrane-supported indication for prophylactic antibiotics — phenoxymethylpenicillin 250 mg twice daily, reducing cellulitis episodes by approximately 50% (Jull et al. Cochrane 2014). This is confirmed in eTG. Each episode of cellulitis causes additional lymphatic damage and accelerates disease progression — prevention is as important as treatment.

Surgical options for refractory lymphoedema (specialist plastic surgery referral):

• Liposuction — for non-pitting fibrotic lymphoedema; removes fibrotic fat deposits; requires lifelong compression post-operatively
• Lymphovenous anastomosis (LVA) — microsurgical connection between lymphatic channels and venous system; most effective in early fibrotic stage; prevents progression
• Vascularised lymph node transfer (VLNT) — transfer of functioning lymph nodes from a donor site; specialist plastic surgery; long-term outcomes variable

C. Cellulitis prevention — the essential safety component

Every patient with lymphoedema needs an active cellulitis prevention and early-treatment plan:

Entry-point prevention:

• Daily moisturisation to prevent skin cracking — urea-based or glycerol-based moisturisers
• Prompt treatment of tinea pedis (lower limb) or tinea manuum (upper limb) — topical or oral antifungal depending on severity
• Cover cuts, abrasions, insect bites with antiseptic and waterproof dressing
• Avoid skin-breaking procedures (injections, venipuncture, acupuncture) in the affected limb
• Careful nail care — avoid cuticle cutting

Early treatment of cellulitis:

• Oral flucloxacillin 500 mg four times daily or cephalexin 500 mg four times daily for at least 7–10 days per eTG
• Compression temporarily reduced (but not removed) during acute cellulitis
• Hospital admission if systemically unwell, spreading despite oral antibiotics, or immunocompromised

Prophylaxis for recurrent cellulitis (≥2 episodes/year):

• Phenoxymethylpenicillin (Penicillin V) 250 mg twice daily — long-term per eTG; review annually

D. Australian operations

Access to CDT in Australia

The Australasian Lymphology Association maintains the certified therapist directory and advocates for Lymphoedema Multi-Disciplinary Clinics (LMDCs) at major cancer centres. Cancer Australia has funded breast-cancer-specific lymphoedema survivorship resources. Wait times for therapists vary significantly by location — rural and remote patients face major access barriers.

Compression garment funding:

• Most compression garments are not on the PBS — patients fund garments privately, which costs approximately $100–$400 per garment (arm sleeve or stocking), requiring replacement every 6 months
• Some private health funds cover compression garments under extras policies
• The National Disability Insurance Scheme (NDIS) covers garments where lymphoedema meets the NDIS access criteria
• State-based cancer support organisations (Cancer Council state branches) sometimes assist with costs

MBS items for lymphoedema

No specific MBS items exist for CDT or lymphoedema management. General-practice consultations involving lymphoedema assessment and care coordination are billed as standard consultation items. Lymphoscintigraphy is covered by nuclear medicine items where clinically indicated. Compression garment prescription by a GP attracts no additional item but supports private health fund claims.

Allied health referrals under Medicare

Patients with a chronic condition and a care plan under MBS item 721 (GP Management Plan) and item 723 (Team Care Arrangement) can access five subsidised allied health visits per year under the chronic disease allied health initiative — this can be used for lymphoedema therapy sessions with a certified lymphoedema therapist who is a registered allied health professional.

E. Special populations

Breast cancer survivors. Upper-limb lymphoedema affects quality of life, work capacity, and mental health. Pre-operative education, post-operative surveillance with limb measurements and BIS, and early referral at stage 0 or 1 (before fibrosis establishes) significantly improve outcomes. The GP’s role is to ask at every cancer survivorship review: “Have you noticed any swelling, tightness, or heaviness in your arm?”

Gynaecological and prostate cancer survivors. Lower-limb lymphoedema is common and frequently undiagnosed. Bilateral lower-limb lymphoedema after pelvic radiation can be difficult to distinguish from venous oedema — lymphoscintigraphy clarifies. Genital lymphoedema (scrotal, labial) also occurs and requires specialist referral.

Patients with obesity. Obesity-related lymphoedema (also called phlebolymphoedema or lipolymphoedema) responds to weight loss; even modest weight reduction improves lymphatic function. Bariatric surgery can result in significant lymphoedema improvement. Compression garments for very large limbs require custom fitting.

Filariasis in migrant or refugee patients. Wuchereria bancrofti is the most common cause of severe secondary lymphoedema globally. In Australia, this presents in patients from tropical endemic regions (sub-Saharan Africa, South-East Asia, Pacific Islands). Diagnosis: serology plus nocturnal blood smear; treatment is diethylcarbamazine plus albendazole; refer to tropical medicine.

Children with primary lymphoedema. Milroy disease or lymphoedema praecox presenting in childhood or adolescence requires paediatric specialist referral. Compression garments must be adjusted frequently to accommodate growth.

When to escalate

• Refer to lymphoedema therapist (ALA-certified) — any diagnosis of lymphoedema, for CDT initiation; do not manage with compression alone without specialist guidance
• Refer to plastic surgery — established lymphoedema not controlled with CDT and compression; consider LVA or VLNT at early fibrotic stage
• Refer to nuclear medicine — lymphoscintigraphy when diagnosis is uncertain or surgical planning is needed
• Refer to vascular surgery or dermatology — where mixed venous-lymphatic aetiology or skin complications complicate management
• Hospital admission for cellulitis — systemic features, spreading despite 48 hours of oral antibiotics, or immunocompromised patient

What this article is and is not

This is general health information drawn from Australasian Lymphology Association guidelines, International Society of Lymphology 2020 Consensus, Therapeutic Guidelines (eTG), Australian Medicines Handbook, and Cancer Australia resources. It is not personal medical advice and does not create a doctor–patient relationship. Lymphoedema management should be co-ordinated with a certified lymphoedema therapist and, for complex cases, a specialist clinic.

For certified therapist directory: Australasian Lymphology Association. For cancer survivorship support: Cancer Council 13 11 20. For consumer information: HealthDirect — Lymphoedema, Better Health Channel — Lymphoedema.

---

Sources cited

1. Australasian Lymphology Association (ALA)
2. International Society of Lymphology — Consensus Document 2020
3. Therapeutic Guidelines (eTG) — Cardiovascular and lymphatic
4. Cancer Australia — Lymphoedema after cancer treatment
5. Australian Medicines Handbook (AMH)
6. Jull AB et al. — Compression for preventing recurrence of venous ulcers. Cochrane 2014
7. NPS MedicineWise — Lymphoedema resources
8. HealthDirect — Lymphoedema
9. Cancer Council Australia
10. Better Health Channel — Lymphoedema
11. MBS Item 721 — GP Management Plan
12. MBS Item 723 — Team Care Arrangement